Synthesis and conformational analysis of a non-amidine factor Xa inhibitor that incorporates 5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine as S4 binding element.
Haginoya
Noriyasu
N
Medicinal Chemistry Research Laboratory, Discovery Research Laboratory, Drug Metabolism & Physicochemical Property Research Laboratory, Daiichi Pharmaceutical Co. Ltd, 1-16-13, Kita-Kasai, Edogawa-ku, Tokyo 134-8630, Japan. hagin9kg@daiichipharm.co.jp
Kobayashi
Syozo
S
Komoriya
Satoshi
S
Yoshino
Toshiharu
T
Suzuki
Makoto
M
Shimada
Takashi
T
Watanabe
Kengo
K
Hirokawa
Yumiko
Y
Furugori
Taketoshi
T
Nagahara
Takayasu
T
D000818:Animals; D001682:Biological Availability; D018360:Crystallography, X-Ray; D015951:Factor Xa / Q000737:chemistry; D065427:Factor Xa Inhibitors; D006801:Humans; D066298:In Vitro Techniques; D008297:Male; D008958:Models, Molecular; D008968:Molecular Conformation; D011485:Protein Binding; D011517:Prothrombin Time; D011725:Pyridines / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D013844:Thiazoles / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology
C492967:2-carbamoyl-4-((6-chloronaphthalen-2-yl)sulfonyl)-1-((5-methyl-4,5,6,7-tetrahydrothiazolo(5,4-c)pyridin-2-yl)carbonyl)piperazine; D065427:Factor Xa Inhibitors; D011725:Pyridines; D013844:Thiazoles; D015951:Factor Xa